Skip to content
Screener

Axsome Therapeutics AXSM Accounts Receivable

Accounts Receivable at other companies

Eli Lilly logo
Eli LillyLLY
$20.08B+41.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$19.05B+6.7%
Alkermes logo
AlkermesALKS
$456.48M+28.6%
AbbVie logo
AbbVieABBV
$12.48B0.0%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$108.22M+2.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$205.23M+78.0%

Other financials

Income statement

See full
Revenue$191.2M+57.4%
Gross profit$176.5M+58.0%
Operating income-$63.4M-11.2%
Net income-$64.5M-8.6%
EPS (diluted)-$1.26-3.3%

Balance sheet

See full
Cash & equivalents$305.1M+1.4%
Total debt$219.9M+4.1%
Total equity$54.6M+2.6%
Total assets$713.6M+19.6%

Cash flow

See full
Operating cash flow-$20.7M+52.3%
CapEx$121.0K-64.2%
Free cash flow-$20.8M+52.4%

Valuation

See full
Market cap$10.95B+113%
Enterprise value$10.87B+114%
P/S15.5×+5.1×

Profitability

See full
Gross margin92.6%+1.1pp
Operating margin-24.4%-9.3pp
Net margin-26.6%-9.8pp
FCF margin-10.2%-3.9pp

Returns & leverage

See full
Return on equity-349.4%+109pp
Debt / equity4×+0.1×
Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.

The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 5:04 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-204274
Line itemMarch 31,2026December 31,2025
Assets
Current assets:
Cash and cash equivalents$305,106$322,933
Accounts receivable, net251,062224,464
Inventories, net31,51527,938
Prepaid and other current assets23,52313,651
Total current assets611,206588,986
Equipment, net567562

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Axsome Therapeutics's accounts receivable?
Axsome Therapeutics (AXSM) reported accounts receivable of $251.06M in Q1 2026.
How has Axsome Therapeutics's accounts receivable changed year-over-year?
Axsome Therapeutics's accounts receivable increased by 55.6% year-over-year, from $161.4M to $251.06M.
What is the long-term trend for Axsome Therapeutics's accounts receivable?
Over 3 years (2022 to 2025), Axsome Therapeutics's accounts receivable has grown at a 81.2% compound annual growth rate (CAGR), from $37.7M to $224.46M.
What does accounts receivable mean?
Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.

Ask your AI about Axsome Therapeutics's accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude